Related references
Note: Only part of the references are listed.Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
Francesco Spagnolo et al.
BMC CANCER (2021)
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab
B. G. Topp et al.
ANNALS OF ONCOLOGY (2021)
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Anne Zaremba et al.
EUROPEAN JOURNAL OF CANCER (2021)
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Justina X. Caushi et al.
NATURE (2021)
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunotherapy rechallenge after nivolumab treatment in advanced non small cell lung cancer in the real-world setting: A national data base analysis
Matteo Giaj Levra et al.
LUNG CANCER (2020)
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
Praful Ravi et al.
JAMA ONCOLOGY (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
Robert Haddad et al.
CANCER (2019)
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A. Beaver et al.
LANCET ONCOLOGY (2018)
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R. Gandara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier et al.
EUROPEAN UROLOGY (2017)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials
Georgina V. Long et al.
JAMA ONCOLOGY (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial
Saby George et al.
JAMA ONCOLOGY (2016)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
